ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Single-Center Cross-Sectional Analysis of Lipid Management in Kidney Transplant Recipients: Is It Time to Reassess KDIGO Guidelines?

R. Saranu1, J. Pandav1, M. Balusu2, J. Azzi1, M. Y. Yeung1, M. McGrath1, E. Abdel-Basset1, S. Gabardi1, A. Chandraker1

1Renal Division, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

Meeting: 2022 American Transplant Congress

Abstract number: 603

Keywords: Dyslipidemia, Kidney transplantation, Lipids

Topic: Administrative » Administrative » 01 - Quality Assurance Process Improvement & Regulatory Issues

Session Information

Session Name: Quality Assurance Process Improvement & Regulatory Issues

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Cardiovascular disease remains the leading cause of mortality after kidney transplant, accounting for more than 30% of total deaths. Dyslipidemia is common following transplantation, and according to the 2013 KDIGO guidelines, statins are recommended in all kidney transplant recipients (KTRs). However, there is no recommendation for specific dose adjustments or routine lipid monitoring. This can lead to untreated or undertreated lipids in KTRs, placing them at a risk for adverse cardiovascular events. Given the potential for disparity and inconsistency, we wanted to analyze the current status of lipid control at our institution.

*Methods: We conducted a single-center, cross sectional analysis of 250 KTRs who were transplanted in the last 4 years. Data that was analyzed included frequency of lipid monitoring (our institutional policy is to check at 3 and 12 months post-transplant), cholesterol levels, cardiovascular risk factors, ASCVD scores, frequency of statin use, statin intolerance, immunosuppressive regimens, etc.

*Results: We found that about 96% KTRs had lipids checked at 3 months, 76% of KTRs had lipids checked at 12 months, 53.2% of KTRs had lipid checked at both 3 months and 12 months. About 30% of KTRs had LDL-C levels>100 mg/dL, 13% had LDL-C levels between 70-100 mg/dL with one of the cardiovascular risk factors. 89.5% of KTRs assessed had at least 1 risk factor (diabetes, hypertension, coronary artery disease and smoking). 54.7% of KTRs that warranted lipid lowering therapy were receiving some form of treatment. Of the total number of KTRs on statins, 10.6% of KTRs reported intolerance (myalgia, hepatotoxicity).

*Conclusions: Our institutional analysis showed sub-optimal lipid control in KTRs, which could be attributed to a lack of clear guidelines on lipid management in KTRs. This is likely due to inadequate studies and weak evidence around the effects of lipid control in KTRs. Based on a survey we conducted across multiple transplant institutions in the Unites States (separate abstract), we found that there are institution-level disparities in the frequency of lipid monitoring and target cholesterol levels for treatment. Since cardiovascular disease remains the leading cause of death in KTRs, optimal lipid control is of utmost importance. For this, we need better and more uniform guidelines for lipid control strategy, which can only be achieved by long term studies assessing benefits on allograft survival and overall outcomes in KTRs.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Saranu R, Pandav J, Balusu M, Azzi J, Yeung MY, McGrath M, Abdel-Basset E, Gabardi S, Chandraker A. A Single-Center Cross-Sectional Analysis of Lipid Management in Kidney Transplant Recipients: Is It Time to Reassess KDIGO Guidelines? [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/a-single-center-cross-sectional-analysis-of-lipid-management-in-kidney-transplant-recipients-is-it-time-to-reassess-kdigo-guidelines/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences